Early-onset growth hormone treatment in Prader-Willi syndrome attenuates transition to severe obesity
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10496058" target="_blank" >RIV/00179906:_____/25:10496058 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00143765 RIV/61988987:17110/25:A2603DNW RIV/44555601:13450/25:43899168 RIV/00216208:11120/25:43928263 and 11 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=JGwMkZsIuJ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=JGwMkZsIuJ</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1515/jpem-2024-0463" target="_blank" >10.1515/jpem-2024-0463</a>
Alternative languages
Result language
angličtina
Original language name
Early-onset growth hormone treatment in Prader-Willi syndrome attenuates transition to severe obesity
Original language description
OBJECTIVES: Subsequent to early life feeding issues, children with Prader-Willi syndrome (PWS) develop hyperphagia and severe obesity. Growth hormone (GH) therapy has been approved in PWS to improve growth, body composition, and BMI. We aimed to clarify the role of age at GH therapy onset on growth and BMI trajectories in children with PWS. METHODS: We analyzed height and BMI in 114 patients (58 boys) from REPAR - Czech national GH registry. From them, 69 started GH therapy prior to 2 y/o (age 0.8 +- 0.4 years; mean +- SD; early-onset group [EO]), and 45 later (age 7.1 +- 4.1 years; late-onset group [LO]). RESULTS: Height-SDS before therapy was similar in all (EO: -1.9 +- 1.2 [mean +- SD]; LO: -1.7 +- 1.1). After the first year of GH therapy, height-SDS in the EO group increased to -1.0 +- 1.2, in the LO group to -0.9 +- 1.1. After 5 years, height fully normalized in all (-0.1 +- 1.1 SDS). The LO children were already obese at treatment initiation (BMI-SDS: 2.9 +- 2.2), and their BMI-SDS decreased after 1 year of GH therapy by 0.9 (p=0.003). The weight in EO children was below average before GH treatment (BMI-SDS: -0.9 +- 1.2) and their BMI-SDS increased to the overweight range of 1.3 +- 2.2 (p<0.001) within the oncoming 3 years. Albeit BMI-SDS was around the obesity limit in most children after 5 years on GH therapy, the highest lifetime BMI-SDS was lower in EO (2.2 +- 2.6) than in LO (3.7 +- 2.2; p<0.001). CONCLUSIONS: GH treatment in PWS normalizes body height. After 5 years of GH therapy, BMI-SDS in EO and LO groups are similar; however, the EO group is exposed to lower maximal BMI-SDS values.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Pediatric Endocrinology & Metabolism
ISSN
0334-018X
e-ISSN
2191-0251
Volume of the periodical
38
Issue of the periodical within the volume
5
Country of publishing house
DE - GERMANY
Number of pages
8
Pages from-to
525-532
UT code for WoS article
001443915200001
EID of the result in the Scopus database
2-s2.0-105000187861